Sequent Scientific Ltd (VIYASH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sequent Scientific Ltd on NSE and BSE, with an AI summary of each filing.
Allotment of ESOP
Others (Uncategorized) · 03 Nov 2026, 12:31 am
Viyash Scientific Approves Allotment of 228,408 Equity Shares Under ESOP Schemes Viyash Scientific Limited approved the allotment of 2,28,408 fully paid-up equity shares of face value Rs. 2 each on 2nd Nov'26 upon the exercise of stock options. This comprises 1,93,000 equity shares allotted at Rs. 86 per share under Sequent ESOP 2020 and 35,408 equity shares at Rs. 101 per share under Viyash ESOP 2026. Consequently, the company's paid-up equity share capital increased from Rs. 88,35,27,100 (44,17,63,550 shares) to Rs. 88,39,83,916 (44,19,91,958 shares). The new shares rank pari passu with existing equity shares.
Intimation of Q2 FY27 Earnings Conference Call / Discussion on Financial Results for Quarter and Half Year Ended September 30, 2026.
Intimation · 14 Nov 2026, 11:00 am
Viyash Scientific Schedules Q2 FY27 Earnings Call for 14th Nov'26 Viyash Scientific Limited (formerly Sequent Scientific Limited) will host its Q2 FY27 earnings conference call on 14th Nov'26 at 11:00 AM IST to discuss financial results for the quarter and half-year ended 30th Sep'26. The call will feature Managing Director & Group CEO Dr. Hari Babu Bodepudi, Executive Director & CEO – Animal Health Rajaram Narayanan, and CFO Ramakant Singani. Investors can access the live session via universal dial-in numbers +91 22 6280 1263 and +91 22 7115 8213 or through Diamond Pass pre-registration.
VIYASH SCIENTIFIC LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 13 Nov 2026, 5:30 am
Viyash Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) ....
Intimation · 13 Nov 2026, 5:30 am
Viyash Scientific Schedules Board Meeting on 13th Nov'26 to Consider Q2 Results Viyash Scientific Limited has scheduled a Board of Directors meeting on 13th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed from 1st Oct'26 until 15th Nov'26, concluding 48 hours post the declaration of the financial results.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 13 Nov 2026, 5:30 am
Please find enclosed herewith update on the Incorporation of step down Subsidiary in Vietnam.
Others (Uncategorized) · 02 Nov 2026, 11:00 pm
Viyash Scientific Incorporates Step-Down Subsidiary Alivira Vietnam to Expand Animal Health Footprint Viyash Scientific Limited announced the incorporation of Alivira Vietnam Company Limited on 30th Oct'26 as a step-down wholly owned subsidiary through Alivira Animal Health Limited (AAHL). Operating in the pharmaceutical sector, the new entity will handle the import, registration, marketing, and distribution of animal health products, APIs, and phytogenic solutions in Vietnam. The expansion involves a cash investment of up to USD 400,000 funded entirely by AAHL, targeting market growth via distributors and strategic direct accounts.
Intimation under Reg 30 of SEBI (LODR) 2015 for Change in Senior Management Personnel.
Change in Management · 20 Oct 2026, 9:14 pm
Viyash Scientific Appoints Dr. Mallikharjuna Rao Nagineni as Senior VP of HR Viyash Scientific Limited announced senior management changes effective 20th Oct'26. The Board approved the appointment of Dr. Mallikharjuna Rao Nagineni as Senior Vice President, Human Resources, designated as Senior Management Personnel. Dr. Nagineni brings over 25 years of experience across organizations such as Mylan Laboratories, Mahindra & Mahindra, and Biological E. Concurrently, Mr. Prasad Lad ceased to be Senior Management Personnel as Vice President – HR & Administration due to forthcoming retirement, effective 20th Oct'26.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for White Oak Capital Management Consultants LLP
Acquisition/ Disposal of Shares · 17 Oct 2026, 5:03 pm
White Oak Trims Stake in Viyash Scientific to 0.14% White Oak Capital Management Consultants LLP offloaded 8,747,392 equity shares, representing a 2.00% stake (1.82% diluted), in Viyash Scientific Ltd (formerly Sequent Scientific Ltd) through open market transactions on 15th Oct'26. Following the disposal, White Oak's managed and advised holdings declined from 9,353,641 shares (2.14% voting capital) to 606,249 shares (0.14% voting capital; 0.13% diluted). Total paid-up equity voting capital stands at 436,875,477 shares, with diluted voting capital at 479,928,915 shares.
Allotment of ESOP
Others (Uncategorized) · 08 Oct 2026, 4:26 pm
Viyash Scientific Approves Allotment of 135,880 Equity Shares Under ESOP Schemes Viyash Scientific Limited approved the allotment of 1,35,880 equity shares of face value Rs. 2 each on 8th Oct'26 following ESOP exercises. The allotment comprises 79,000 shares at Rs. 86 per share under the Sequent ESOP 2020 and 56,880 shares at Rs. 101 per share under the Viyash ESOP 2026. Consequently, the company's paid-up equity share capital expanded from Rs. 88,32,55,340 (44,16,27,670 shares) to Rs. 88,35,27,100 (44,17,63,550 shares). The newly allotted shares rank pari passu with existing equity shares.
Completion of acquisition of BioForLife Italia S.r.l.
Others (Uncategorized) · 01 Oct 2026, 11:16 pm
Viyash Scientific Completes 100% Acquisition of Italy's BioForLife Viyash Scientific's step-down subsidiary, Alivira Animal Health Limited, Ireland, completed the 100% acquisition of BioForLife Italia S.r.l. on 1st Oct'26. The transaction includes an upfront base consideration of EUR 15.0 million plus agreed net financial adjustments as of 30th Jun'26, alongside a deferred consideration of EUR 1.976 million subject to closing date financial position adjustments. Following the closure, BioForLife Italia has become a step-down wholly owned subsidiary, with Alivira appointing its representatives to the board.
Allotment of ESOP
Others (Uncategorized) · 18 Sept 2026, 5:56 pm
Viyash Scientific Approves Allotment of 1.11 Mn Equity Shares Under ESOP Schemes Viyash Scientific Limited approved the allotment of 11,07,309 equity shares of face value Rs. 2 each on 18th Sep'26 via ESOP exercises. The allotment includes 9,26,333 shares at Rs. 86 each under Sequent ESOP 2020 and 1,80,976 shares at Rs. 101 each under Viyash ESOP 2026. Consequently, the company's paid-up equity share capital increased from Rs. 88.10 cr (44,05,20,361 shares) to Rs. 88.33 cr (44,16,27,670 shares). The newly allotted shares rank pari passu with existing equity shares.
Update on proposed acquisition of BioForLife Italia S.r.l
Others (Uncategorized) · 09 Sept 2026, 12:11 am
Viyash Scientific Secures Italian FDI Approval for BioForLife Italia Acquisition Viyash Scientific Limited announced that its step-down wholly owned subsidiary, Alivira Animal Health Limited, Ireland, has received regulatory approval under Italian FDI/Golden Power regulations to acquire a 100% shareholding in Milan-based BioForLife Italia S.r.l. Factoring in remaining customary closing formalities and conditions, the expected completion timeline has been revised to within two months from 8th Sep'26. All other material terms and conditions of the transaction remain unchanged from previous disclosures.
Allotment of ESOP
Others (Uncategorized) · 04 Sept 2026, 4:43 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CA Harbor Investment & CA Hull Investments
Acquisition/ Disposal of Shares · 27 Aug 2026, 7:55 pm
Promoter Group Entities Reduce Stake in Viyash Scientific Promoter group entities CA Harbor Investments and CA Hull Investments sold stakes in Viyash Scientific via open market transactions on Aug 26, '26. CA Harbor sold 2.48 crore shares (5.67% stake), reducing its holding to 24.47%. CA Hull sold 2.56 crore shares (5.86% stake), lowering its holding to 25.31%. Post-sale, their combined promoter group holding in the company stands at 49.78%, down from a pre-sale total of 61.31%. The disclosure was made under SEBI SAST regulations on Aug 27, '26.
Earning call Transcript Q1 FY 2026-27
Transcript · 16 Aug 2026, 4:54 pm
Audio Recording of Earnings call pertaining to the unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026
Audio / Video · 13 Aug 2026, 1:18 am
Viyash Scientific Publishes Q1 FY27 Earnings Call Audio Recording Viyash Scientific Limited has released the audio recording of its earnings call held on 12 Aug'26. The call discussed the unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. The recording is available on the company's website, as per SEBI regulations. Viyash Scientific, formerly known as Sequent Scientific, trades under the symbols VIYASIL (NSE) and 512529 (BSE).
Investor Presentation Q1 FY 2026-2027
Investor Presentation · 12 Aug 2026, 3:32 pm
Viyash Scientific Q1 FY27: Strong EBITDA Growth and Margin Expansion Viyash Scientific reported robust Q1 FY27 results, with revenue growing 19.5% YoY to ₹9,464 Mn. Adjusted EBITDA surged 59.2% YoY to ₹2,047 Mn, driving a significant margin expansion of 530 bps to 21.6%. The Formulations segment grew 33% YoY, led by Emerging Markets (+36%), India (+63%), and USA (+60%). The company strengthened its deleveraging efforts, reducing Net Debt/EBITDA to 0.1x. Strategic progress includes the announced acquisition of Bio For Life in Italy to expand its companion animal business in Europe.
Voting results and scrutinizer Report
Annual General Meeting · 12 Aug 2026, 2:02 am
Viyash Scientific Shareholders Approve All Resolutions at 41st AGM At its 41st AGM on Aug 11, '26, Viyash Scientific Limited shareholders passed all proposed resolutions. The special resolution to adopt a new Articles of Association received 97.99% votes in favour. Other key ordinary resolutions, including the adoption of FY26 financial statements and director re-appointments, passed with over 99.8% approval. Resolutions ratifying Cost Auditor remuneration for FY26 and FY27 also passed with near-unanimous support. Overall voter turnout was approximately 72.6% of total share capital.
Voting results and scrutinizer Report
Annual General Meeting · 12 Aug 2026, 2:01 am
Viyash Scientific Shareholders Approve All Resolutions at 41st Annual General Meeting Viyash Scientific announced that all resolutions at its 41st AGM on Aug 11, '26, were passed with requisite majority. Key approvals included the adoption of audited financial statements for FY26 and the re-appointment of directors Dr. Haribabu Bodepudi and Mr. Rajaram Narayanan. A special resolution to adopt a new set of Articles of Association was also passed with 97.99% votes in favour. Overall voter turnout for the resolutions was approximately 72.5% of total outstanding shares, with promoter and public institutions showing high participation.
Outcome of the 41st AGM held on August 11, 2026
Annual General Meeting · 11 Aug 2026, 11:48 pm
Press Release for Q1 FY 2026-27
Press Release · 11 Aug 2026, 9:13 pm
Viyash Scientific Reports Strong Q1 FY27 with 115% PAT Growth Viyash Scientific posted robust Q1 FY27 results with consolidated revenue of ₹9,464 million, up 19.5% YoY. Strong operating leverage drove EBITDA up 59.2% to ₹2,047 million, with margins expanding significantly to 21.6% from 16.2% YoY. Profit After Tax (PAT) surged 114.9% YoY to ₹793 million. The company cited robust execution and benefits from its integration strategy as key drivers. The balance sheet strengthened with Net Debt/EBITDA at a low 0.1x. An earnings call is scheduled for 12 Aug'26.
Allotment of ESOP under Viyash Scientific Limited -Employee Stock Option Scheme 2026
Others (Uncategorized) · 11 Aug 2026, 6:49 pm
Viyash Board Approves Q1FY27 Results and Rs. 400 Cr Debt-to-Equity Conversion Viyash Scientific's board, on 11 Aug'26, approved Q1FY27 financial results. For Q1, consolidated PAT was Rs. 792.9 Mn on revenues of Rs. 9,546.7 Mn. The board also approved allotting 10,30,775 equity shares at Rs. 101/share under its ESOP scheme. Furthermore, it approved a subscription of up to Rs. 400.02 Cr in its subsidiary, Alivira Animal Health, via a rights issue to convert an intercompany loan into equity. The board also greenlit the incorporation of a new step-down subsidiary in Vietnam.
Outcome of Board Meeting
Outcome · 11 Aug 2026, 6:43 pm
Viyash Scientific Board Approves Q1FY27 Results and Key Corporate Actions Viyash Scientific's board, on 11-Aug-'26, approved Q1FY27 results and key corporate actions. Consolidated revenue was ₹9,546.70 Mn, with a PAT of ₹792.90 Mn. The board also approved allotting 10,30,775 equity shares at ₹101/share under its ESOP scheme. Additionally, it sanctioned an investment of up to ₹4,000.22 Mn in its wholly-owned subsidiary, Alivira Animal Health Ltd (AAHL), via a rights issue to convert intercompany loans to equity. A new step-down subsidiary will also be incorporated in Vietnam with a proposed investment of up to USD 400,000.
Unaudited Financial Results for Q1 FY 2026-2027
Financial Result · 11 Aug 2026, 6:40 pm
Sequent Scientific Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 9,464 (+19.5% YoY | +2.9% QoQ) ■ EBITDA: 1,784 (+50.2% YoY | -3.2% QoQ) ■ EBITDA Margin (%): 18.8 (+385 bps YoY | -118 bps QoQ) ■ PAT: 659 (+107.1% YoY | +26.4% QoQ) ■ EPS (INR): 1.47 (+101.4% YoY | +25.6% QoQ)
Intimation of Q1 FY27 Earnings Conference Call / Discussion on Financial Results for Quarter Ended June 30, 2026
Intimation · 12 Aug 2026, 3:30 pm
Viyash Scientific Sets Q1FY27 Earnings Conference Call for Aug 12 Viyash Scientific Limited has scheduled its Q1FY27 earnings conference call for 12th Aug'26 at 3:30 PM IST. The management will discuss financial results for the quarter ending 30th Jun'26. Key speakers include Managing Director & Group CEO Dr. Hari Babu Bodepudi, Executive Director and CEO – Animal Health Mr. Rajaram Narayanan, and CFO Mr. Ramakant Singani. The event provides a forum for analysts and investors to engage with the company's top leadership regarding recent performance and outlook.